Search the Newsreel

Cielo to Shift Brazil Payment Terminals From Traditional SIMs

Amdocs (NASDAQ: DOX) announced that Brazilian payment services provider Cielo has selected its Remote eSIM Manager to modernize connectivity across Cielo’s nationwide payment terminal fleet in Brazil. This transition will move Cielo from traditional SIM cards to an intelligent, software-defined connectivity model, enabling secure …

Cielo Selects Amdocs to Bring Intelligent Connectivity to Its Entire Brazilian Payment Terminal Network

Cielo, a major Brazilian payment services provider, has partnered with Amdocs to modernize its nationwide payment terminal network. By adopting Amdocs Remote eSIM Manager, Cielo will transition from traditional SIM cards to an intelligent, software-defined connectivity model, ensuring continuous and optimized payment processing across …

Optimum launches redesigned billing platform with Amdocs By Investing.com

Optimum has partnered with Amdocs to launch a redesigned customer billing experience. The new digital platform uses visual insights and AI to provide clearer monthly bills, explain changes from previous statements, and reduce the need for customers to contact customer service for billing inquiries. …

PLDT Home Selects Amdocs to Modernize Core Business Platform, Advancing Cloud-Ready Transformation

Upgrade will boost business agility, streamline customer operations and establish a scalable foundation for future digital innovation JERSEY CITY, NJ / ACCESS Newswire / August 5, 2026 / Amdocs (NASDAQ:DOX), a leading provider of software and services to communications and media companies, today announced …

Sunrise Extends its Strategic Collaboration with Amdocs, Advancing its CRM Evolution with aOS

The Swiss telecommunications operator is to modernize and evolve its CRM with aOS, Amdocs's agentic operating system for telco, to help its frontline staff work more efficiently JERSEY CITY, NJ / ACCESS Newswire / August 5, 2026 / Amdocs (NASDAQ:DOX), a leading provider of …

Lumen to Build Service Platform Across AWS, Azure and Google Cloud

Amdocs announced an expanded cloud collaboration with Lumen Technologies to modernize Lumen's enterprise service orchestration and order management platform on Amazon Web Services (AWS). This initiative builds on previous migrations to Google Cloud and Microsoft Azure, establishing a multi-cloud environment. Amdocs' aOS and AI-driven …

Sunrise Plans AI Analytics to Help Call Center Staff Work Faster

Amdocs announced that Swiss telecom operator Sunrise has extended its collaboration to modernize Sunrise's CRM environment using Amdocs' aOS, an agentic operating system for telcos. This initiative aims to integrate AI analytics and streamline workflows for customer service representatives, leading to faster issue resolution …

Liberty Latin America Announces 10-Year Strategic Engagement with Amdocs

Liberty Latin America has announced a 10-year strategic engagement with Amdocs to manage its end-to-end IT ecosystem. This partnership aims to transform Liberty Latin America's IT operations into an AI-driven model, accelerating innovation, enhancing customer experience, and achieving significant cost savings. Amdocs will collaborate …

Amdocs Limited Reports Third Quarter Fiscal 2026 Results

Amdocs Limited reported solid Q3 fiscal 2026 results with revenue of $1.17 billion, up 2.7% year-over-year as reported, and reiterated its fiscal 2026 revenue growth outlook. The company announced a multi-year strategic engagement with Liberty Latin America to manage and transform its IT domain …

Crocs Shares Slide After Report Alleges Company Has a 'Trick for Dodging Taxes'

Crocs (NASDAQ: CROX) shares fell after a New York Times report alleged the company used a Maltese subsidiary to funnel international profits and dodge taxes. The report sparked market uneasiness due to potential IRS scrutiny and back-tax liabilities, leading traders to lock in gains. …

Here's What Key Metrics Tell Us About Amdocs (DOX) Q3 Earnings

Amdocs (DOX) reported Q3 2026 revenue of $1.17 billion, a 2.7% year-over-year increase, and EPS of $1.84. While revenue slightly missed the Zacks Consensus Estimate, the company's EPS matched expectations. Key geographic revenue metrics showed North America with a modest increase, while Rest of …

How to Buy Crocs Inc. Stock (CROX)

This

Amdocs (DOX) Could Be 31% Undervalued Following Q2 Earnings Focus

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Amdocs (DOX) is in focus as it prepares to report Q2 earnings this Wednesday after market close, with the market watching for the expected 2.7% …

Vivo Selects Amdocs to Advance OSS Modernization with Upgrade to Amdocs CES2X

Vivo has renewed its strategic collaboration with Amdocs, upgrading its Customer Experience Suite (CES) to CES2X and aligning licensing capacity to support its growing customer base. This initiative modernizes Vivo's OSS environment, enhancing service activation, inventory, and provisioning capabilities, and establishing a foundation for …

How Renewed Analyst Confidence Ahead of Earnings Will Impact Amdocs (DOX) Investors

Amdocs recently announced it would report quarterly earnings after the market close, with consensus expecting revenue growth compared with the same period last year, reversing a prior decline. Analysts have largely reaffirmed their estimates and highlighted Amdocs as a comparatively attractive value option versus …

Amdocs (NASDAQ:DOX) Updates FY 2026 Earnings Guidance

Amdocs VP Anjali Mahajan on women in tech, leadership, and navigating the AI shift

Anjali Mahajan, VP and Head of Engineering Services at Amdocs, discusses her 29-year career in tech, balancing motherhood with leadership, and fostering opportunities for women in the industry. She emphasizes the importance of connecting technology to business and preparing the next generation for an …

Is Stronger Guidance And Bigger Buybacks Altering The Investment Case For Crocs (CROX)?

Precision Trading with Oculis Holding Ag (OCS) Risk Zones

Oculis Holding Ag (OCS) shows divergent sentiment across different time horizons, suggesting choppy conditions with elevated downside risk. The article provides institutional trading strategies including long, momentum breakout, and short strategies, along with a multi-timeframe signal analysis detailing support and resistance levels. It emphasizes …

Crocs (CROX) Just Flashed Golden Cross Signal: Do You Buy?

Crocs (CROX) has shown a technical "golden cross" signal, with its stock price moving above the 20-day moving average, suggesting a short-term bullish trend. The company has also seen positive earnings estimate revisions, solidifying the bullish case. Investors might want to monitor CROX for …

Crocs stock hits 52-week high at 140.46 USD

Crocs Inc. (CROX) stock has reached a new 52-week high of $140.46, reflecting a 32.77% increase over the past year and a 57.73% year-to-date return in 2026. Despite this significant rally, InvestingPro analysis suggests the stock still trades below its Fair Value. The company's …

DOX or ROP: Which Is the Better Value Stock Right Now?

Investors interested in stocks from the Computers - IT Services sector have probably already heard of Amdocs (DOX) and Roper Technologies (ROP). But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look. Everyone …

Crocs, Inc. (NASDAQ:CROX) Receives Average Recommendation of "Moderate Buy" from Brokerages

Crocs, Inc. (NASDAQ:CROX) has received an average "Moderate Buy" rating from twenty research firms, with an average twelve-month price target of $135.09. The company recently reported strong second-quarter results, exceeding revenue and earnings expectations, but its third-quarter guidance disappointed investors due to uneven growth …

Oculis Announces FDA Pre-IND Feedback Regarding Privosegtors Clinical Development Plan

(RTTNews) - Oculis Holding AG (OCS) announced positive FDA pre-IND feedback regarding Privosegtors clinical development plan in acute multiple sclerosis relapses. The FDA Division of Neurology provided positive feedback supporting a regulatory pathway for Privosegtor in acute multiple sclerosis relapses. The FDA confirmed that …

FDA Says Oculis Can Cross-Reference Data for Planned MS Relapse Trial

Oculis (OCS) received positive pre-IND feedback from the U.S. FDA regarding its development strategy for Privosegtor in treating acute multiple sclerosis (MS) relapses. The FDA confirmed that existing data can be cross-referenced, eliminating the need for additional preclinical studies, and supported the proposed clinical …

Oculis Receives Positive FDA Feedback Supporting Development Pathway for Privosegtor in Acute Multiple Sclerosis Relapses

Oculis Holding AG has received positive FDA feedback for its neuroprotective drug Privosegtor, supporting its regulatory pathway for treating acute multiple sclerosis (MS) relapses. The FDA confirmed that existing data from the Phase 2 ACUITY study can be used for a new Investigational New …

Is Now The Time To Look At Buying Crocs, Inc. (NASDAQ:CROX)?

This article analyzes Crocs, Inc. (NASDAQ:CROX) as a potential investment opportunity. It will likely delve into the company's valuation, recent performance, future outlook, and other financial metrics to determine if the current stock price presents an attractive buying point for investors.

Amdocs Ltd (DOX) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Amdocs Ltd (DOX), indicating its current earnings forecast score and analyst ratings. It highlights that the average price target is $103.01, with most analysts recommending a "Buy" trend. The article also includes expected revenue and EPS for …

Amdocs (DOX) Backlog And AI Push Put Valuation Back In Focus

Amdocs (DOX) has garnered attention due to a significant 12-month backlog of $4.28 billion and new customer agreements for its agentic operating system, alongside the acquisition of Matrixx Software. Despite recent positive developments and a short-term stock rebound, the company's shares are down year-to-date …

Crocs Inc (CROX) Stock Up 3.5% but GF Value Says Overvalued -- G

Crocs Inc (CROX) shares have risen 3.5%, reaching $128.01, and showing strong year-to-date and annual gains. Despite this performance and a strong GF Score™ of 84/100, GuruFocus's GF Value™ suggests the stock is 7.5% overvalued at $119.09. Insider activity reveals significant selling without purchases, …

7G Capital Management LLC Takes $3.44 Million Position in Crocs, Inc. $CROX

7G Capital Management LLC has acquired a new stake of 41,500 shares in Crocs, Inc. (NASDAQ:CROX) worth approximately $3.44 million, making it their 10th largest position. This news comes as other institutional investors also adjust their holdings in Crocs, and analysts provide new price …

Crocs (CROX) Stock Climbs As Raised Outlook Meets Tariff Margin Pressure

Piper Sandler reiterates Crocs stock rating on accounting change

Piper Sandler reiterated an Overweight rating and a $150.00 price target for Crocs Inc. (NASDAQ:CROX) after the company's latest results, noting that while gross margin was softer, the company’s guidance for Q3 2026 was impacted by an accounting change. Despite some investor concerns regarding …

Should Value Investors Buy Amdocs (DOX) Stock?

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in …

Crocs, Inc. Q2 2026: Revenue $1.18B, EPS $4.13— 10-Q Summary

Crocs, Inc. reported strong Q2 2026 results, with revenue increasing by 2.6% to $1.18 billion and diluted earnings per share reaching $4.13, a significant turnaround from a prior-year loss. The revenue growth was primarily driven by higher average selling prices for Crocs, while the …

Press Release: Crocs, Inc. Reports Record Second Quarter 2026 Results; Raises Full-Year 2026 Outlook

Crocs, Inc. announced record second-quarter results for 2026, with revenue reaching $1.2 billion, a 15% increase year-over-year. The company reported